Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 02:30 ET | Source: Laigo Bio

Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity

Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEOLaigo Bio’s SureTAC™ membrane protein degradation technology targets...
December 03, 2025 16:30 ET | Source: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS, 03 déc. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actionscomposant le capital socialNombre total de droits de...
December 03, 2025 16:30 ET | Source: Cellectis Inc.

Monthly information on share capital and company voting rights

PARIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
December 03, 2025 11:58 ET | Source: Nika Pharmaceuticals, Inc.

Nika Pharmaceuticals, Inc. (NIKA) Progress Update

Nika Pharmaceuticals, Inc. (OTCQB: NIKA) appeared on The Street Reports podcast and shares Nika Europe's factory progress and expectations for 2026.
December 03, 2025 03:30 ET | Source: Actithera

Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer

Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shapeBrings over 15 years...
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
December 02, 2025 09:00 ET | Source: ADARx Pharmaceuticals

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors
December 02, 2025 08:27 ET | Source: Pluristyx, Inc.

CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.
December 02, 2025 08:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the...